“It is baseless, and we will pay a tremendous price in terms of illnesses and deaths.” That brutal judgment by Michael Osterholm, a veteran infectious disease expert at the University of Minnesota, was his reaction to the cancellation by the U.S. Department of Health and Human Services of $500 million of federal funding for mRNA vaccine research. The move, led by Secretary Robert F. Kennedy Jr., terminates 22 BARDA contracts that were funding research on next-generation COVID‑19, flu, and other high-consequence pathogen vaccines.
The numbers Kennedy quoted in favor of the reductions were derived from a 181‑page collection of some 400 papers though as Stanford infectious disease physician Jake Scott noted, “the vast majority” were unrelated to vaccine safety. The majority were COVID‑19 infection outcome trials, rather than immunization, and most were of mice injected directly into the brain or the circulatory system routes inapplicable to human vaccination. Missing altogether were the large-scale, peer-reviewed trials proving the safety and efficacy of mRNA vaccines, such as a Danish trial with over one million recipients of boosters that found “no statistically significant risk” for 29 potential side effects, including myocarditis.
The lost evidence is excellent. A global analysis by John P.A. Ioannidis approximated that 2020-September 2024 vaccination efforts saved approximately 4 million lives globally, a figure he called “conservative.” Earlier models by the Commonwealth Fund approximated the United States burden averted to be in excess of 3 million deaths and 18 million hospitalizations during the first two years alone. A 2022 Lancet study approximated 20 million lives saved globally in the first year alone.
The virtue of the mRNA platform is its agility and velocity. Detailed by molecular biologists, it begins with the design of the messenger RNA sequence in silico from the genome of the pathogen. Synthetic nucleotides are built into the target mRNA, capped, polyadenylated, purified, and encapsulated into lipid nanoparticles designer carriers that fuse with cell membranes to transfer the genetic information. Upon delivery, the host’s ribosomes translate the mRNA into a viral antigen that stimulates both antibody and T-cell immune responses. Because the design process is digital and cell-free, vaccines can be manufactured in weeks instead of the several months it takes for egg-based or inactivated-virus strategies. That fast turnaround is not science fiction.
During the pandemic, boosters were reconfigured to counter new SARS‑CoV‑2 variants arising, and big trials, such as Moderna’s mRNA‑1273 COVE trial, demonstrated long-term protection. In ongoing follow-up through April 2023, the primary series reduced severe COVID-19 during the Delta wave by 83%, and a 50-microgram booster lowered Omicron BA.1 cases by more than half in the first two months post-vaccination. New vaccines, like the 2023–2024 XBB.1.5-containing mRNA-1273.815, have been found to be 60.2% effectiveness against COVID‑19 hospitalizations in all adult age groups. The BARDA contracts that were terminated were not limited to respiratory viruses. Several targeted mRNA vaccines for HIV, malaria, tuberculosis, and even therapy use in cancer targets regions where the platform’s value for encoding multiple antigens or patient-specific tumor neoantigens offers unique advantages. mRNA-based melanoma vaccines and personalized cancer immunotherapies are already underway in clinical trials, applying the same speed-to-design principles to target tumor-specific mutations.
Global competitors are moving in the opposite direction. The European Union and China are investing heavily in mRNA manufacturing capacity, aiming to integrate the technology into seasonal flu programs and pandemic preparedness frameworks. As Rick Bright, former BARDA director, warned, “We’re taking our country from 2025 back to 1940,” ceding leadership in a technology that could define the next century of vaccinology.
Kennedy has argued that mRNA vaccines “encourage mutation” and become worthless with “one mutation,” claims virologists reject. MRNA vaccines do not cause the virus to mutate they do that all on their own, neurologist Steven Novella wrote. By cutting viral transmission, vaccination cuts opportunities for mutation. And because mRNA vaccines can be easily retooled, no one mutation ever rendered them obsolete.
The political framing of this decision obscures its strategic implications. Beyond pandemic response, mRNA’s modularity makes it a critical countermeasure platform against engineered pathogens a deterrent in biodefense strategy. Jennifer Nuzzo, director of the Pandemic Center at Brown University, underscored the risk: When there’s the next pandemic, we’re going to be caught flat-footed. It absolutely leaves the country vulnerable.
Meanwhile, foreign and private research will be driving the science. But in the absence of federal investment, the United States risks becoming a consumer, rather than a manufacturer, of next-generation vaccines a position that could prove a heck of a lot more expensive than the half-billion just shaved.
